Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Authors:
Top Cited Papers
- 1 February 2020
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 21 (2) , 242-249
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP18ck0106214)
This publication has 18 references indexed in Scilit:
- Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE studyAnnals of Oncology, 2016
- Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)Cancer, 2014
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnnals of Oncology, 2014
- Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving ChemotherapyJournal of Clinical Oncology, 2012
- Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III TrialJournal of Supportive Oncology, 2011
- Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASEJournal of Clinical Oncology, 2011
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnnals of Oncology, 2010
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996